Hydroxycarbamide Arrow

Hydroxycarbamide, the active ingredient in Hydroxycarbamide Arrow, is an antimetabolite presented as an oral formulation for oral use. It inhibits DNA synthesis and is employed in the treatment of sickle cell disease, polycythemia vera, essential thrombocythemia and chronic myelogenous leukemia, helping to control disease progression and symptom burden.

GNH USA supplies Hydroxycarbamide Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Hydroxycarbamide is an antimetabolite used in hematologic disorders and certain leukemias.

- Sickle cell disease: reduces frequency of painful crises and may decrease transfusion requirements. - Polycythemia vera: helps control elevated red blood cell mass and lowers thrombosis risk. - Essential thrombocythemia: lowers platelet counts and mitigates thrombotic complications. - Chronic myelogenous leukemia: used as part of therapy to suppress leukemic cell proliferation.

Hydroxycarbamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Hair thinning: reversible loss of scalp hair. - Mouth ulcers: painful lesions in the oral mucosa. - Skin discoloration: brownish pigmentation of the skin. - Fatigue: persistent tiredness. - Elevated liver enzymes: abnormal liver function tests.

Serious or Rare Side Effects: - Aplastic anemia: severe bone marrow failure requiring urgent medical attention. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea.

When prescribing Hydroxycarbamide, clinicians should consider several precautionary measures to ensure safe use.

- Baseline blood counts: obtain CBC before initiation and monitor regularly. - Renal function: assess creatinine clearance, adjust if impairment present. - Liver function: monitor transaminases during therapy. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist. - Drug interactions: review concomitant medications for potential additive myelosuppression. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents (e.g., azathioprine, cyclophosphamide): may cause severe bone marrow suppression. - Antiretroviral protease inhibitors (e.g., ritonavir): can increase hydroxycarbamide plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Allopurinol: may potentiate hematologic toxicity; monitor blood counts. - Phenytoin: may reduce hydroxycarbamide effectiveness; consider dose adjustment. - Live vaccines: immunosuppression may increase infection risk; evaluate timing.